You may be aware that the Lyrica patent for epilepsy and generalised anxiety disorder (GAD) has expired. A second patent still exists for the use of Lyrica in the treatment of neuropathic pain.
It is our understanding that generic versions are becoming available that will be for use only in epilepsy or GAD.
At present the generic pregabalin is listed in the drug tariff as category C so the reimbursement for the generic is currently based on the brand Lyrica.
If pregabalin is prescribed for the treatment of neuropathic pain (the patented indication), pharmacists should supply the brand.
This is an ongoing, complex issue and we have been liaising with UK colleagues on the matter. We will keep you informed of any developments as they occur.